Table of Contents Author Guidelines Submit a Manuscript
International Journal of Nephrology
Volume 2011, Article ID 203579, 3 pages
http://dx.doi.org/10.4061/2011/203579
Case Report

Tranexamic Acid Treatment of Life-Threatening Hematuria in Polycystic Kidney Disease

1Division of Gastroenterology, The University of Western Ontario, London, Ontario, Canada N6H 3K7
2Division of Nephrology, Dalhousie University, Halifax, NS, Canada B3H 1V7

Received 21 February 2011; Accepted 4 April 2011

Academic Editor: Nuket Bavbek

Copyright © 2011 Turki AlAmeel and Michael West. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. A. Gabow, I. Duley, and A. M. Johnson, “Clinical profiles of gross hematuria in autosomal dominant polycystic kidney disease,” American Journal of Kidney Diseases, vol. 20, no. 2, pp. 140–143, 1992. View at Google Scholar
  2. C. J. Dunn and K. L. Goa, “Tranexamic acid: a review of its use in surgery and other indications,” Drugs, vol. 57, no. 6, pp. 1005–1032, 1999. View at Publisher · View at Google Scholar
  3. U. Zwettler, M. Zeier, K. Andrassy, S. Geberth, and M. Rambausek, “Treatment of gross hematuria in autosomal dominant polycystic kidney disease with aprotinin and desmopressin acetate,” Nephron, vol. 60, no. 3, p. 374, 1992. View at Google Scholar · View at Scopus
  4. A. Rannikko, A. Pétas, and K. Taari, “Tranexamic acid in control of primary hemorrhage during transurethral prostatectomy,” Urology, vol. 64, no. 5, pp. 955–958, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. P. M. Mannucci, “Hemostatic drugs,” New England Journal of Medicine, vol. 339, no. 4, pp. 245–253, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Mezzano, O. Panes, B. Muñoz et al., “Tranexamic acid inhibits fibrinolysis, shortens the bleeding time and improves platelet function in patients with chronic renal failure,” Thrombosis and Haemostasis, vol. 82, no. 4, pp. 1250–1254, 1999. View at Google Scholar
  7. M. Sabovi, J. Lavre, and B. Vujkovac, “Tranexamic acid is beneficial as adjunctive therapy in treating major upper gastrointestinal bleeding in dialysis patients,” Nephrology Dialysis Transplantation, vol. 18, no. 7, pp. 1388–1391, 2003. View at Google Scholar
  8. B. Vujkovac and M. Sabovic, “A successful treatment of life-threatening bleeding from polycystic kidneys with antifibrinolytic agent tranexamic acid,” Blood Coagulation and Fibrinolysis, vol. 17, no. 7, pp. 589–591, 2006. View at Publisher · View at Google Scholar
  9. J. R. Koo, Y. K. Lee, Y. S. Kim, W. Y. Cho, H. K. Kim, and N. H. Won, “Acute renal cortical necrosis caused by an antifibrinolytic drug (tranexamic acid),” Nephrology Dialysis Transplantation, vol. 14, no. 3, pp. 750–752, 1999. View at Google Scholar · View at Scopus
  10. A. R. Odabaş, R. Cetinkaya, Y. Selçuk, H. Kaya, and U. Coşkun, “Tranexamic-acid-induced acute renal cortical necrosis in a patient with haemophilia A,” Nephrology Dialysis Transplantation, vol. 16, no. 1, pp. 189–190, 2001. View at Google Scholar · View at Scopus
  11. L. Tenborn, “Fibrinolytic inhibitors in the management of bleeding disorders,” Treatment of Hemophilia, no. 42, pp. 1–15, 2007. View at Google Scholar
  12. L. Andersson, O. Eriksson, P. O. Hedlund, H. Kjellman, and B. Lindqvist, “Special considerations with regard to the dosage of tranexamic acid in patients with chronic renal diseases,” Urological Research, vol. 6, no. 2, pp. 83–88, 1978. View at Google Scholar